Healthcare Jun 24, 2022 11:07 AM (GMT+8) · EqualOcean
On June 23, Hewlett Packard Sen Pharma, a veteran Chinese pharmaceutical company established for nearly 30 years, announced that it had received a notice from the New York Stock Exchange that it did not meet the criteria for continuous listing. Prior to this, on June 17, the Chinese innovative pharmaceutical company kangnaide biological also received a "delisting" warning because its share price was lower than US $1 for 30 consecutive trading days in the past. According to statistics, up to now, there are about 31 Chinese large health enterprises listed in the US stock market. In 2022, about one-third of them will be "difficult to ensure safety", or they will be abandoned by the market because of mediocre clinical data or insufficient innovation ability.

This text is a result of machine translation.